Software engineering
Designing a next-generation virtual clinical trial platform
Learn more
Homepage zuehlke.com
Pharma
Software-as-a-Medical Device transforming liver diagnostic tests
Zühlke supports the design and delivery of a next-generation blood-based diagnostic test that improves patient experience and the reliability of diagnostic results.
-
Fibronostics is looking to launch a next-generation Software-as-a-Medical Device (SaMD) solution that can help better assess liver health via a non-invasive blood-based diagnostic test
-
Zühlke works closely with Fibronostics to design and develop the solution throughout the entire product lifecycle, from the development of the product roadmap to the design and delivery of the solution
-
Zühlke plays an active role as a trusted technology advisor with deep expertise in healthcare solutions, supporting Fibronostics in driving better clinical outcomes for both clinicians and patients
In the field of clinical diagnostics, a liver biopsy is the current standard of testing and assessing liver damage. This procedure is invasive, unpleasant, and can lead to complications of varying severity.
Fibronostics — a global diagnostics company that leverages algorithmic diagnostics and AI to screen and measure liver, kidney and other chronic diseases, is looking to launch a next-generation blood-based diagnostic test to better assess liver health.
The new product, built on AI and algorithm technology, uses biomarkers from the patient’s blood to determine the extent of liver damage, making it less invasive while having a high prognostic value.
Zühlke supports Fibronostics to design, build and deliver the product with the goal of revolutionising the current landscape of clinical diagnostics.
Aligning around customer outcomes
To better understand the project requirements and assess the product market fit, the team deep dived into a discovery workshop with Fibronostics through in-depth research and user interviews. A product roadmap was created together with Fibronostics that defines the timeline, project scope and prioritise features for the team to develop. To ensure a highly scalable solution design, our engineers followed proper testing processes to ensure product performance, compatibility and security so that new features can be added with ease in future.
“It is crucial that we work collaboratively on the product roadmap so that the implementation is aligned with Fibronostic’s long-term vision. I feel proud to be a part of a team making meaningful impact in the world by improving the lives of those affected by liver diseases.”
Scalable agility
The team adopted an agile development and delivery approach to ensure close feedback loops throughout the product delivery lifecycle. With this incremental approach, the team was able to focus on implementation and delivery of the product , leveraging on Zühlke’s multidisciplinary engineering capabilities and deep understanding of Software-as-a-Medical Device (SaMD).
“Zühlke’s technical expertise and experience in the healthcare industry have been instrumental in helping us realise our vision of designing a next-generation liver diagnostic test”
Redefining the future of liver diagnostic tests
Zühlke works closely with Fibronostics to design and deliver a new blood-based diagnostic test from end-to-end, from the development of the product roadmap to the design and delivery of the solution. With this new solution in place, doctors and clinicians working in primary care facilities will be able to better test and assess their patient’s liver health, driving better clinical outcomes for both clinicians and patients.
